FDA Granted Orphan Drug Designation to Linnaeus Therapeutics’ LNS8801
The U.S. Food and Drug Administration (FDA) has granted Linnaeus Therapeutics’ LNS8801 an orphan drug designation for the treatment of patients with metastatic cutaneous melanoma. The FDA’s Office of Orphan […]